Clovis Withdraws Rubraca’s Original Ovarian Cancer Indication Shows FDA Emphasis On Survival Data

 
• By Bridget Silverman
  
'Withdrawal' hand written note laying on pile of folders and documents

More from Approval Standards

More from Pathways & Standards